Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Depreciation & Amortization (CF) (2016 - 2025)

Orthopediatrics (KIDS) has disclosed Depreciation & Amortization (CF) for 10 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 40.3% to $5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.1 million, a 10.69% increase, with the full-year FY2025 number at $21.1 million, up 10.69% from a year prior.
  • Depreciation & Amortization (CF) was $5.6 million for Q4 2025 at Orthopediatrics, up from $5.3 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.6 million in Q4 2025 to a low of $2.5 million in Q1 2021.
  • A 5-year average of $4.1 million and a median of $4.0 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 84.65% in 2021, then dropped 23.02% in 2024.
  • Orthopediatrics' Depreciation & Amortization (CF) stood at $2.8 million in 2021, then rose by 25.27% to $3.5 million in 2022, then soared by 47.36% to $5.2 million in 2023, then dropped by 23.02% to $4.0 million in 2024, then skyrocketed by 40.3% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for KIDS's Depreciation & Amortization (CF) are $5.6 million (Q4 2025), $5.3 million (Q3 2025), and $5.2 million (Q2 2025).